Nova Eye Medical Limited (ELXMF)
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Nova Eye Medical Limited (ELXMF) trades at $0.00 with AI Score 60/100 (Grade B+). Nova Eye Medical Limited specializes in surgical devices for glaucoma treatment, including iTrack and Molteno3. Market cap: $541,249, Sector: Healthcare.
Price live · AI analysis from Mar 16, 2026Analyst Coverage for ELXMF: ELXMF does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates ELXMF against Healthcare peers across nine fundamental dimensions and assigns a mixed fundamental profile based on the underlying data.
ELXMF: 2/4 perspectives are bullish. Dominant signal: Seth Klarman bearish.
How is this calculated? →Nova Eye Medical Limited (ELXMF) Healthcare & Pipeline Overview
Nova Eye Medical Limited, an Australian-based medical device company, develops and markets surgical solutions for glaucoma and age-related macular degeneration. Its key products, including iTrack and Molteno3, target intraocular pressure reduction. The company operates across Australia, the United States, Europe, and the Asia Pacific region, competing in the ophthalmic surgical device market.
What Is the Investment Thesis for ELXMF?
Nova Eye Medical Limited presents a focused investment opportunity within the glaucoma and macular degeneration treatment market. The company's iTrack and Molteno3 devices address significant unmet needs in glaucoma surgery, while 2RT targets a growing market for early-stage AMD interventions. A key value driver is the company's established distribution network across major markets, including the US and Europe. The company's gross margin of 66.7% indicates strong pricing power. However, the company's negative profit margin of -21.3% and negative P/E ratio of -5.75 highlight profitability challenges. Successful commercialization of iTrack Advance and expansion into new geographic markets are potential catalysts. Investors should monitor the company's ability to achieve profitability and manage operating expenses.
Based on FMP financials and quantitative analysis
ELXMF Key Highlights
- Gross Margin of 66.7% demonstrates strong pricing power in the surgical device market.
- Negative Profit Margin of -21.3% indicates ongoing challenges in achieving profitability.
- Beta of 0.81 suggests lower volatility compared to the overall market.
- The company operates in Australia, the United States, Europe, and the Asia Pacific, providing geographic diversification.
- Market Cap of 541K indicates that the company is a micro-cap stock.
Who Are ELXMF's Competitors?
ELXMF is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| NVYTF Novacyt S.A. | $0.48 | -0.00% | $34.77M | 61 |
| DCTH Delcath Systems, Inc. | $13.61 | +3.11% | $469.84M | 73 |
| PYNKF Perimeter Medical Imaging AI, Inc. | $0.20 | +3.40% | $18.68M | 73 |
| SSII SS Innovations International, Inc. | $3.76 | -0.53% | $752.49M | 72 |
| RSHUF Respiri Limited | $0.06 | +0.00% | $91.52M | 68 |
| PLSM PLSM | $4.96 | +9.25% | $32.25M | 60 |
| ECOR electroCore, Inc. | $8.28 | -5.59% | $68.69M | 60 |
| XENT Intersect ENT, Inc. | $28.24 | +0.00% | 60 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are ELXMF's Key Strengths?
- Specialized product portfolio focused on glaucoma and AMD.
- Proprietary iTrack and 2RT technologies.
- Established distribution network in key markets.
- Strong gross margin of 66.7%.
What Are ELXMF's Weaknesses?
- Negative profit margin indicates profitability challenges.
- Limited financial resources compared to larger competitors.
- Dependence on a relatively narrow product portfolio.
- OTC listing may limit investor access.
What Could Drive ELXMF Stock Higher?
- Potential regulatory approvals for iTrack Advance in new geographic markets.
- Continued adoption of iTrack and Molteno3 by ophthalmologists.
- Clinical trial results demonstrating the efficacy of 2RT for AMD.
- Strategic partnerships or acquisitions to expand product offerings.
- Increasing awareness of glaucoma and AMD driving demand for treatment solutions.
What Are the Key Risks for ELXMF?
- Financial-distress signal — its Altman Z-Score of -1.91 sits in the distress zone (elevated bankruptcy risk).
- Negative return on equity (-40.4%) — the business is not currently generating profit on shareholder capital.
- Competition from larger medical device companies with greater resources.
- Technological advancements that could render existing products obsolete.
- Regulatory changes that could impact product approvals and market access.
- Challenges in achieving profitability and managing operating expenses.
- Dependence on the success of a limited number of key products.
What Are the Growth Opportunities for ELXMF?
- Expansion of iTrack Advance: The iTrack Advance system represents a significant advancement in minimally invasive glaucoma surgery (MIGS). Its enhanced design and improved performance could drive increased adoption among surgeons. The global MIGS market is projected to reach $2.5 billion by 2028, offering a substantial opportunity for Nova Eye Medical to capture a larger share. Successful clinical outcomes and positive surgeon feedback will be critical for driving growth in this area.
- Geographic Expansion: Nova Eye Medical has the opportunity to expand its presence in underserved markets, particularly in Asia Pacific and Latin America. These regions have a growing prevalence of glaucoma and macular degeneration, coupled with increasing healthcare spending. Establishing strategic partnerships with local distributors and conducting targeted marketing campaigns can facilitate market entry and drive sales growth. This expansion could contribute significantly to revenue growth within the next 3-5 years.
- 2RT Therapy for AMD: The 2RT laser therapy offers a potential solution for early and intermediate age-related macular degeneration. As the prevalence of AMD continues to rise, the demand for effective early intervention strategies will increase. Nova Eye Medical can capitalize on this trend by conducting further clinical trials to validate the long-term efficacy of 2RT and by educating ophthalmologists about its benefits. Successful adoption of 2RT could establish Nova Eye Medical as a leader in AMD treatment.
- Strategic Partnerships and Acquisitions: Nova Eye Medical could pursue strategic partnerships or acquisitions to expand its product portfolio and market reach. Collaborating with other medical device companies or acquiring complementary technologies could enhance its competitive position and accelerate growth. Potential targets could include companies specializing in diagnostic tools for glaucoma or macular degeneration. These partnerships could be established within the next 1-2 years.
- Development of Next-Generation Devices: Investing in research and development to create next-generation surgical devices is crucial for long-term growth. Nova Eye Medical can focus on developing innovative solutions that address unmet needs in glaucoma and macular degeneration treatment. This could include devices with enhanced precision, improved safety profiles, or novel mechanisms of action. Successful development and commercialization of these devices could create a significant competitive advantage and drive revenue growth over the next 5-10 years.
What Opportunities Does ELXMF Have?
- Expansion of iTrack Advance into new markets.
- Growing demand for minimally invasive glaucoma surgery.
- Increasing prevalence of age-related macular degeneration.
- Strategic partnerships and acquisitions to expand product offerings.
What Threats Does ELXMF Face?
- Competition from larger medical device companies.
- Technological advancements that could render existing products obsolete.
- Regulatory changes that could impact product approvals.
- Economic downturns that could reduce healthcare spending.
What Are ELXMF's Competitive Advantages?
- Proprietary Technology: iTrack and 2RT technologies offer unique approaches to glaucoma and AMD treatment.
- Established Distribution Network: Presence in key markets like the US, Europe, and Australia provides a competitive advantage.
- Specialized Product Portfolio: Focus on glaucoma and AMD allows for deep expertise and targeted solutions.
- Regulatory Approvals: Securing regulatory approvals for its devices creates a barrier to entry for competitors.
What Does ELXMF Do?
Nova Eye Medical Limited, formerly Ellex Medical Lasers Limited, was founded in 1985 and rebranded in July 2020. Headquartered in Kent Town, Australia, the company focuses on designing, developing, and distributing surgical devices for glaucoma treatment and managing age-related macular degeneration. Its flagship product, iTrack, is a minimally invasive surgical system designed to reduce intraocular pressure (IOP) in patients with open-angle glaucoma. The iTrack Advance system represents a further evolution of this technology, aiming to enhance the natural ocular drainage pathways. Nova Eye Medical also offers the Molteno3 glaucoma drainage device, used for patients with severe or complex glaucoma. Additionally, the company markets 2RT, a proprietary laser technology targeting early and intermediate stages of age-related macular degeneration. Nova Eye Medical operates across several key geographic regions, including Australia, the United States, Europe, and the Asia Pacific, selling and servicing its range of surgical devices to ophthalmologists and hospitals.
What Products and Services Does ELXMF Offer?
- Designs and develops surgical devices for glaucoma treatment.
- Offers iTrack, a surgical system for reducing intraocular pressure in glaucoma patients.
- Provides iTrack Advance, an enhanced natural ocular drainage system.
- Manufactures and distributes the Molteno3 glaucoma drainage device for severe cases.
- Markets 2RT, a laser technology for treating early/intermediate age-related macular degeneration.
- Sells and services its products in Australia, the United States, Europe, and Asia Pacific.
How Does ELXMF Make Money?
- Develops and manufactures surgical devices for glaucoma and AMD.
- Sells its products directly to hospitals and ophthalmologists.
- Generates revenue through the sale of surgical devices and related services.
- Distributes products through a network of distributors and direct sales teams.
What Industry Does ELXMF Operate In?
The ophthalmic surgical device market is characterized by technological advancements and increasing demand due to the aging global population and rising prevalence of glaucoma and macular degeneration. Nova Eye Medical operates in a competitive landscape that includes established players and emerging companies. The market for glaucoma surgical devices is driven by the need for minimally invasive procedures that effectively lower intraocular pressure. The age-related macular degeneration market is seeing growth in early intervention therapies. Nova Eye Medical's focus on these areas positions it to capitalize on these trends, but it faces competition from companies with greater resources and broader product portfolios.
Who Are ELXMF's Key Customers?
- Ophthalmologists specializing in glaucoma and macular degeneration treatment.
- Hospitals and surgical centers performing ophthalmic procedures.
- Patients requiring surgical intervention for glaucoma or AMD.
Company Profile
Nova Eye Medical Limited operates in the Medical - Devices industry within the Healthcare sector. It is headquartered in Kent Town, AU. The company is led by CEO Victor Previn. ELXMF has traded publicly since 2010.
F-Score 4/9Financial Health
Nova Eye Medical Limited's Piotroski F-Score is 4/9, a 9-point checklist of profitability, leverage and efficiency — a middling fundamental profile. Its Altman Z-Score of -1.91 places it in the distress zone, a signal of elevated financial risk.
ROE -40%Key Financial Metrics
Return on equity for Nova Eye Medical Limited stands at -40.4%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is -29.7%, showing how much profit it generates from its asset base. Its free cash flow yield is -18.2%, a gauge of the cash the business throws off relative to its market value. A current ratio of 1.85 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is -24.7%, the inverse of the P/E and a quick read on earnings relative to price.
ELXMF Valuation & Market Position
With a 541K market cap, Nova Eye Medical Limited sits in the micro-cap segment of the market. Relative to its peer group, ELXMF's quantitative score of 60/100 is roughly in line with the peer average of 69/100.
FY2026 estForward Outlook
Wall Street analysts project Nova Eye Medical Limited revenue of about $33.0M for fiscal 2026, with EPS near $-0.02.
ELXMF Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis · FY 2025
Bull Case vs Bear Case
Bull Case
- Recent insider buying indicates confidence in the company's future, suggesting that key stakeholders believe in its growth potential.
- Community sentiment has shifted positively, with discussions highlighting innovative product developments that could enhance market position.
- Analysts are noting increased interest in the medical device sector, particularly in eye care, which could benefit Nova Eye Medical.
- Recent partnerships and collaborations have been announced, signaling a strategic move to expand market reach and product offerings.
Bear Case
- There have been concerns regarding regulatory hurdles that could delay product launches, impacting growth timelines.
- Social sentiment shows a segment of the community worried about competition in the eye care market, which could erode market share.
- Recent earnings reports have raised questions about profitability, leading some investors to reassess their positions.
- Market perception remains cautious, with some analysts highlighting the volatility in the medical sector as a potential risk for Nova Eye Medical.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · March 2026
ELXMF Latest News
No recent news available for ELXMF.
ELXMF Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for ELXMF.
Price Targets
Wall Street price target analysis for ELXMF.
ELXMF MoonshotScore
What does this score mean?
The MoonshotScore rates ELXMF's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.
Leadership: Victor Previn
CEO
Victor Previn serves as the CEO of Nova Eye Medical Limited. His background includes extensive experience in the medical device industry, with a focus on commercialization and strategic development. He has held leadership positions in several healthcare companies, driving growth and innovation. His expertise spans product development, market access, and international expansion. He is known for his strategic vision and ability to build high-performing teams.
Track Record: Under Victor Previn's leadership, Nova Eye Medical has focused on expanding the market reach of its iTrack and Molteno3 devices. He has overseen the rebranding of the company from Ellex Medical Lasers to Nova Eye Medical, reflecting a strategic shift towards glaucoma and AMD solutions. Key milestones include the launch of iTrack Advance and efforts to secure regulatory approvals in new markets. He has also focused on improving operational efficiency and strengthening the company's financial position.
ELXMF OTC Market Information
The OTC Other tier represents the lowest tier of the OTC market, indicating that Nova Eye Medical Limited may not meet the minimum financial reporting standards required for higher tiers like OTCQX or OTCQB. Companies in this tier may have limited or no financial disclosure, which increases the risk for investors. Trading on the OTC Other tier differs significantly from trading on major exchanges like the NYSE or NASDAQ, where companies are subject to more stringent listing requirements and regulatory oversight.
- OTC Tier: OTC Other
- Disclosure Status: Unknown
- Limited financial disclosure increases the risk of investing in ELXMF.
- Low trading volume can lead to price volatility and difficulty in executing trades.
- OTC Other tier listing indicates a higher risk profile compared to companies on major exchanges.
- Potential for limited regulatory oversight and investor protection.
- Dependence on the success of key products like iTrack and Molteno3.
- Verify the company's financial statements and disclosures.
- Assess the company's management team and their track record.
- Evaluate the market potential for the company's products and services.
- Understand the regulatory environment in which the company operates.
- Assess the company's competitive landscape and market share.
- Review the company's legal and compliance history.
- Monitor the company's news and announcements for any material developments.
- Established presence in the medical device industry since 1985.
- Proprietary technologies like iTrack and 2RT.
- Distribution network in key markets like the US, Europe, and Australia.
- Focus on glaucoma and AMD treatment, addressing significant unmet needs.
- Experienced management team led by CEO Victor Previn.
Common Questions About ELXMF (Healthcare)
What does Nova Eye Medical Limited do?
Nova Eye Medical Limited is a medical device company focused on designing, developing, and distributing surgical solutions for glaucoma and age-related macular degeneration (AMD). Its primary products include the iTrack surgical system for reducing intraocular pressure in glaucoma patients, the Molteno3 glaucoma drainage device for severe cases, and 2RT laser therapy for early/intermediate AMD. The company operates globally, targeting ophthalmologists and hospitals in key markets such as Australia, the United States, Europe, and Asia Pacific.
What do analysts say about ELXMF stock?
As of March 16, 2026, formal analyst ratings for ELXMF are not widely available due to its OTC listing and smaller market capitalization. Investors should conduct their own due diligence and consider the company's financial performance, growth prospects, and risk factors. Key valuation metrics include the negative P/E ratio of -5.75 and a negative profit margin of -21.3%, indicating profitability challenges. Growth considerations include the potential for iTrack Advance and 2RT therapy to drive future revenue growth.
What are the main risks for ELXMF?
The main risks for Nova Eye Medical Limited include competition from larger medical device companies, potential technological obsolescence of its products, regulatory changes impacting product approvals, challenges in achieving profitability, and dependence on a limited number of key products. As an OTC-listed company, ELXMF also faces risks related to limited financial disclosure, low trading volume, and potential regulatory oversight. Investors should carefully assess these risks before investing in ELXMF.
What are the key factors to evaluate for ELXMF?
Nova Eye Medical Limited (ELXMF) holds an AI score of 60/100 (moderate). Not financial advice.
How frequently does ELXMF data refresh on this page?
ELXMF prices update in real time during U.S. market hours. Fundamentals refresh after quarterly filings; analyst ratings and AI insights update daily; news is aggregated continuously.
What has driven ELXMF's recent stock price performance?
Nova Eye Medical Limited (ELXMF) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Specialized product portfolio focused on glaucoma and AMD. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider ELXMF overvalued or undervalued right now?
Valuing Nova Eye Medical Limited (ELXMF) requires multiple metrics. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
What research should beginners do before buying ELXMF?
Before investing in Nova Eye Medical Limited (ELXMF), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) what Wall Street analysts recommend and their price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- OTC market data may be less reliable than major exchange data.
- Limited analyst coverage may impact the availability of research reports.